Key clinical finding: Whole-gland high-intensity focused ultrasound (HIFU) may be an effective therapeutic option for patients with localized prostate cancer, particularly in those with D’Amico low- and intermediate-risk disease.
Major finding: Five-year biochemical recurrence-free survival rates for D’Amico low-, intermediate-, and high-risk groups were 85.7%, 82.7%, and 45.2%, respectively. Moreover, 5-year salvage treatment-free survival rates for the 3 risk groups were 71.4%, 69.2%, and 30.6%, respectively. The rates of adverse events were comparable with those of other studies.
Study details: A single-center cohort study included 128 patients with primary localized prostate cancer treated with whole-gland HIFU.
Disclosures: The study did not receive any specific funding. The authors declared no conflicts of interest.
Wu Y-T et al. PLoS One. 2020 Jul 23. doi: 10.1371/journal.pone.0236026.